Key Points
- Director Phoebe Yang sold 1,290 Doximity shares for approximately $34,456 at an average price of $26.71, reducing her stake by 4.96%. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
- Doximity’s latest quarterly results exceeded expectations, with adjusted EPS of $0.29 versus the $0.16 consensus estimate and revenue of $156.62 million, up 7.3% year over year.
- Analysts maintain a consensus “Hold” rating with an average price target of $31.95, while securities class-action litigation and related law-firm notices introduce additional legal and reputational uncertainty.
Doximity, Inc. (NYSE:DOCS - Get Free Report) Director Watkin Phoebe Yang sold 1,290 shares of the stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $26.71, for a total value of $34,455.90. Following the sale, the director owned 24,744 shares in the company, valued at approximately $660,912.24. This trade represents a 4.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Doximity Stock Down 1.9%
NYSE DOCS opened at $27.95 on Friday. Doximity, Inc. has a fifty-two week low of $17.15 and a fifty-two week high of $74.33. The stock has a market cap of $4.98 billion, a price-to-earnings ratio of 32.89, a price-to-earnings-growth ratio of 22.29 and a beta of 1.22. The business has a fifty day moving average of $25.19 and a 200-day moving average of $23.26.
Doximity (NYSE:DOCS - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.16 by $0.13. The business had revenue of $156.62 million for the quarter. Doximity had a return on equity of 18.06% and a net margin of 25.48%.The firm's revenue was up 7.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.36 earnings per share. As a group, analysts anticipate that Doximity, Inc. will post 0.74 EPS for the current year.
Doximity News Roundup
Here are the key news stories impacting Doximity this week:
- Neutral Sentiment: Director Phoebe Yang sold 1,290 Doximity shares for approximately $34,456 at an average price of $26.71, reducing her holdings by about 5%. The sale was executed under a Rule 10b5-1 plan, which generally indicates it was scheduled in advance rather than based on current company information. SEC insider transaction filing
- Negative Sentiment: Several investor-rights law firms publicized a securities class action against Doximity and certain officers. The lawsuit covers investors who purchased DOCS shares between August 8, 2024, and May 13, 2026, and alleges violations of federal securities laws. The allegations have not been proven, but the litigation creates potential legal costs, reputational risk, and uncertainty around the company’s prior disclosures. Kaplan Fox class action announcement
- Negative Sentiment: Law firms including Kaplan Fox, SBS, Robbins LLP, Bronstein Gewirtz & Grossman, Pomerantz, Robbins Geller, and Rosen urged eligible shareholders to seek lead-plaintiff status before the November 16, 2026 deadline. The repeated notices increase visibility of the lawsuit and may weigh on sentiment even though they do not represent new operational or financial developments at Doximity. Robbins LLP class action notice
Hedge Funds Weigh In On Doximity
Several large investors have recently added to or reduced their stakes in DOCS. Carmignac Gestion grew its holdings in Doximity by 127.8% in the 1st quarter. Carmignac Gestion now owns 4,311,997 shares of the company's stock valued at $100,480,000 after buying an additional 2,418,971 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Doximity by 24.7% during the 2nd quarter. Wellington Management Group LLP now owns 3,135,113 shares of the company's stock worth $65,022,000 after acquiring an additional 621,464 shares during the period. Royal Bank of Canada lifted its holdings in shares of Doximity by 28.4% during the 1st quarter. Royal Bank of Canada now owns 206,282 shares of the company's stock worth $4,806,000 after acquiring an additional 45,618 shares during the period. Quantinno Capital Management LP boosted its position in shares of Doximity by 420.5% in the first quarter. Quantinno Capital Management LP now owns 140,345 shares of the company's stock worth $3,270,000 after acquiring an additional 113,380 shares during the last quarter. Finally, Rhenman & Partners Asset Management AB boosted its position in shares of Doximity by 174.1% in the fourth quarter. Rhenman & Partners Asset Management AB now owns 372,750 shares of the company's stock worth $16,505,000 after acquiring an additional 236,750 shares during the last quarter. 87.19% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of research firms have issued reports on DOCS. BMO Capital Markets restated a "market perform" rating and issued a $30.00 target price on shares of Doximity in a report on Friday, August 7th. Bank of America reissued an "underperform" rating and issued a $20.00 price objective (down from $38.00) on shares of Doximity in a research report on Monday, June 29th. Canaccord Genuity Group set a $36.00 price objective on shares of Doximity in a research note on Friday, August 7th. Truist Financial upped their price objective on shares of Doximity from $19.00 to $24.00 and gave the company a "hold" rating in a research note on Thursday, August 13th. Finally, Wolfe Research upgraded shares of Doximity to an "outperform" rating in a research report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, fourteen have issued a Hold rating and three have issued a Sell rating to the company's stock. According to MarketBeat, Doximity currently has an average rating of "Hold" and an average target price of $31.95.
Check Out Our Latest Analysis on Doximity
Doximity Company Profile
(
Get Free Report)
Doximity, Inc operates a digital platform designed for U.S. medical professionals. Its network enables physicians, nurse practitioners, physician assistants and other healthcare providers to connect with colleagues, exchange clinical information and access professional resources.
The company offers tools for telehealth and care coordination, including video and phone-based communication services, as well as digital faxing and secure messaging capabilities. Doximity also provides medical news and research content tailored to healthcare professionals.
Doximity generates additional business through recruiting and marketing solutions that help healthcare organizations reach clinicians and promote employment opportunities, services and products.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
